药物基因组学的创新模型 关键结果识别和干预
Ryley Uber1,2, Vanessa A Hayduk3, Alison Flango4
1Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA. ruber@geisinger.edu.
The pharmacogenomics journal
|October 2, 2025
概括
药物基因组学测试结果可能很难在医疗保健环境中返回. 这项研究提出了一个机构协议,以安全地将药物基因组学结果整合到患者护理中,以进行持续的测试.
科学领域:
- 临床药理学 临床药理学
- 遗传学 是一个遗传学.
- 医疗保健信息学 医疗保健信息学
背景情况:
- 药物基因组学 (PGx) 测试提供了个性化的医学见解,但在结果交付方面面临挑战.
- 在整个医疗保健系统中,结果的可变回报可能会推迟关键干预.
- 为了有效地将PGx整合到患者护理中,需要采用标准化的方法.
研究的目的:
- 为安全和有效地返回药物基因组学试验结果提出一个模型.
- 建立一个机构协议,将新的PGx发现纳入持续的患者管理.
- 支持规模化和持续的药物基因组学测试倡议.
主要方法:
- 开发一个新的药物基因组学结果回报的机构协议.
- 专注于将新的PGx结果安全整合到现有的患者护理工作流程中.
- 为在医疗保健机构中规模化和持续实施而设计的框架.
主要成果:
- 拟议的模型有助于安全地返回药物基因组学结果.
- 机构协议允许将PGx发现纳入患者护理.
- 这种方法支持扩大药物基因组学测试.
结论:
- 对于药物基因组学结果的安全和持续回报,一个机构协议至关重要.
- 这个模型解决了当前PGx结果交付中的挑战.
- 有效的整合协议是实现临床实践中药物基因组学的好处的关键.
更多相关视频
相关概念视频
Analysis of Population Pharmacokinetic Data
682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K


